Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Luohuazizhu is a traditional Chinese herbal medicine derived from Callicarpa nudiflora Hook. et Arn. It is available in various formulations including granules and suppositories. The primary active constituents are diterpenoids such as callicarpic acid A and related labdane-type compounds. Luohuazizhu exhibits anti-inflammatory, hemostatic, and detoxifying properties. Its mechanism of action involves inhibition of the NLRP3 inflammasome pathway and regulation of inflammatory cytokines. Clinically, it has been widely used in China for the treatment of digestive system disorders such as gastrointestinal hemorrhage, hepatitis, inflammation (including cervicitis), colorectal adenoma (a precursor to colorectal cancer), acute tonsillitis, urinary tract infections with bleeding, and other inflammatory conditions[1][3][7][10]. The product was first approved in China in 1995.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on luohuazizhu.